Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa

Experience with delamanid (Dlm) is limited, particularly among HIV-positive individuals. We describe early efficacy and safety data from a programmatic setting in South Africa. This was a retrospective cohort study of patients receiving Dlm-containing treatment regimens between November 2015 and Aug...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohr, Erika, Hughes, Jennifer, Reuter, Anja, Trivino Duran, Laura, Ferlazzo, Gabriella, Daniels, Johnny, De Azevedo, Virginia, Kock, Yulene, Steele, Sarah Jane, Shroufi, Amir, Ade, Serge, Alikhanova, Natavan, Benedetti, Guido, Edwards, Jeffrey, Cox, Helen, Furin, Jennifer, Isaakidis, Petros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485275/
https://www.ncbi.nlm.nih.gov/pubmed/29724920
http://dx.doi.org/10.1183/13993003.00017-2018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485275/
https://www.ncbi.nlm.nih.gov/pubmed/29724920
http://dx.doi.org/10.1183/13993003.00017-2018

Ejemplares similares